Cogent Biosciences Inc COGT

$28.56 -0.58 (-1.99%)

Valuation

Market cap
4,969,269,000
Revenue TTM
$0
Net income TTM
$-328,940,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.43

Trading

Volume
1,150,700
Avg volume
2,164,368
Day's range
$28.45 – $29.02
Shares out
173,994,000
Stochastic %K
2%
Beta
0.36
Analysts
Strong Buy
Price target
$55.91

Price

Company profile

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations i...

Show more

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
(617) 945-5576
Website
https://www.cogentbio.com
Address
180 Third Avenue, 4th Floor, Waltham, United States

Latest news

Stocktwits

BiotechSwings Nov 15, 11:30 PM
Last week of the three is one day doing all the work Nov 30 $COGT bezuclastinib plus sunitinib in GIST after imatinib, Priority Review, PEAK did 16.5 months median PFS vs 9.2 Nov 30 Vertex povetacicept in IgAN, Priority Review on the accelerated path, RAINIER cut proteinuria 52% from baseline that is the hard date list through Dec 6. Vanda on Dec 12 is next after it imo
0 replies
Skoufc1 Nov 15, 5:15 PM
$COGT Smmt got a crl...
0 replies
spaarrow1 Nov 14, 9:39 AM
$COGT bounce down to 16usd
0 replies
spaarrow1 Nov 14, 9:39 AM
$COGT soon 20 usd. They Will dump
1 replies
StMichaelTwits Nov 13, 10:58 PM
$COGT $INO I betted large INO would get approval, and for tomorrow I bet $CYTK gets approval and COGT imo 85% it will get approval in a few weeks..dang Christmas coming early folks.
1 replies
StMichaelTwits Nov 13, 2:41 PM
$COGT If dble bottom is 27.90, then hit that g spot soon so it can bounce really hard over 34
1 replies
StMichaelTwits Nov 13, 2:34 PM
$COGT High short interest..Shorts will move this up, once they exit. It will be soon, they do not want to be caught up on some big buys. They know chances of approval are very high. It will wake up soon... 💎
0 replies
ZackInvest008 Nov 12, 7:35 PM
$COGT Choppy. Closes over 30 to end the week. Expect run up to start next week. Mark this post to show how wrong I always am, for future reference.
1 replies